EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PD-L1 Expression in Prostate Cancer: Anatomopathological Features, Methodological Pitfalls, and Therapeutic Potential

Ludovica Pepe, Cristina Pizzimenti, Pietro Tralongo iD, Valeria Zuccalà iD, Antonio Ieni, Pietro Pepe, Gabriele Ricciardi iD, Vincenzo Cianci iD, Cristina Mondello, Maurizio Martini iD, Guido Fadda, Vincenzo Fiorentino iD

International Journal of Molecular Sciences · 13.02.2026 · 27 (4) · 1797

DOI: 10.3390/ijms27041797 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.02.2026. Verfasst von Ludovica Pepe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy. Hauptthemen laut MEDLINE: B7-H1 Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Programmed death-ligand 1 (PD-L1) has become a central biomarker and therapeutic target across multiple solid tumors, yet its clinical meaning in prostate cancer (PCa) remains unsettled. PCa is commonly described as an immunologically ‘cold’ malignancy, characterized by limited baseline cytotoxic T-cell infiltration and a tumor microenvironment (TME) shaped by myeloid-driven suppression and low neoantigen load in many cases. Against this background, PD-L1 expression in PCa is typically low in untreated primary tumors but can increase in aggressive variants, advanced stages, and metastatic castration-resistant disease, where therapy pressure and microenvironmental cues may select for immune-evasive phenotypes. The literature is further complicated by major analytic variability, including differences in antibody clones and platforms, scoring algorithms (tumor proportion score, combined positive score, immune-cell scoring), cut-offs, tissue sites and timing, and pre-analytical variables such as fixation and decalcification. Collectively, available studies suggest that higher PD-L1 expression tends to be associated with adverse clinicopathological features and may enrich for responses to immune checkpoint inhibitors in selected settings, but PD-L1 immunohistochemistry alone is insufficient as a stand-alone predictive tool in unselected patients. This review synthesizes the biological drivers of PD-L1 regulation in PCa, dissects key methodological sources of heterogeneity in PD-L1 assessment, summarizes clinicopathological and therapeutic correlations, and outlines emerging biomarkers and approaches (including mismatch repair deficiency/microsatellite instability, tumor mutational burden, gene-expression signatures, liquid biopsies, and neuro-immune interactions) that may enable more actionable patient stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenProstatic NeoplasmsHumansMaleTumor MicroenvironmentBiomarkers, TumorGene Expression Regulation, NeoplasticImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

PD-L1biomarkerimmune checkpoint inhibitorsimmunotherapyliquid biopsymismatch repairprostate cancertumor microenvironmenttumor mutational burden

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
  • PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical Sciences, Dental Sciences and Morpho-functional Imaging, University of Messina, 98125 Messina, Italy.
  • Anatomic Pathology Unit, Papardo Hospital, 98158 Messina, Italy.
  • Urology Unit, Cannizzaro Hospital, 95126 Catania, Italy.
  • Istituto Clinico Polispecialistico C.O.T. Cure Ortopediche Traumatologiche s.p.a., 98124 Messina, Italy.
  • Section of Legal Medicine, Department of Biomedical Sciences, Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.

ORCID-Profile: Pietro Tralongo, Valeria Zuccalà, Gabriele Ricciardi, Vincenzo Cianci, Maurizio Martini, Vincenzo Fiorentino

Zitieren

APA

Pepe, L., Pizzimenti, C., Tralongo, P., Zuccalà, V., Ieni, A., Pepe, P., Ricciardi, G., Cianci, V., Mondello, C., Martini, M., Fadda, G., & Fiorentino, V. (2026). PD-L1 Expression in Prostate Cancer: Anatomopathological Features, Methodological Pitfalls, and Therapeutic Potential. International Journal of Molecular Sciences, 27(4), 1797. https://doi.org/10.3390/ijms27041797

Vancouver

Pepe L, Pizzimenti C, Tralongo P, Zuccalà V, Ieni A, Pepe P, et al. PD-L1 Expression in Prostate Cancer: Anatomopathological Features, Methodological Pitfalls, and Therapeutic Potential. International Journal of Molecular Sciences. 2026;27(4):1797. doi:10.3390/ijms27041797

BibTeX
@article{Pepe2026,
  author = {Pepe, Ludovica and Pizzimenti, Cristina and Tralongo, Pietro and Zuccalà, Valeria and Ieni, Antonio and Pepe, Pietro and Ricciardi, Gabriele and Cianci, Vincenzo and Mondello, Cristina and Martini, Maurizio and Fadda, Guido and Fiorentino, Vincenzo},
  title = {PD-L1 Expression in Prostate Cancer: Anatomopathological Features, Methodological Pitfalls, and Therapeutic Potential},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {4},
  pages = {1797},
  doi = {10.3390/ijms27041797}
}
Kostenlos starten →